CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

By Robin Sawka, BioCentury Staff | Apr 4, 2020 | 12:57 AM GMT
Editor's note: Updated on Apr 8, 2020 at 5:45 PM GMT

CureVac AG said Deputy Chairman Jean Stéphenne will become chairman. He is the former president and chairman of the biologicals unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). It's another management change for the biotech as it moves forward with its COVID-19 mRNA vaccine. Deputy CEO Franz-Werner Haas took over as CEO in March, just five days after Ingmar Hoerr replaced Daniel Menichella as CEO. Also last month, CureVac received an €80 million ($88.0 million) EIB loan to expand its COVID-19 manufacturing capacity (see "CureVac CEO Hoerr Takes

Read the full 862 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE